Literature DB >> 29177165

Theranostics of Neuroendocrine Tumors.

Sze Ting Lee1, Harshad R Kulkarni2, Aviral Singh2, Richard P Baum2.   

Abstract

Somatostatin receptor positron emission tomography/computed tomography using 68Ga-labeled somatostatin analogs is the mainstay for the evaluation of receptor status in neuroendocrine tumors (NETs). This translates towards better therapy options, with increasing evidence of peptide receptor radionuclide therapy (PRRT) as the treatment of choice for advanced or progressive NETs. There are benefits in progression-free and overall survival as well as a significant improvement in clinical condition. In patients with progressive NETs, fractionated, personalized PRRT results in good therapeutic responses with no significant severe hematological and/or renal toxicity, thus improving quality of life.

Entities:  

Keywords:  Diagnosis; Neuroendocrine tumor, NET; Peptide receptor radionuclide therapy, PRRT; Positron emission tomography/computed tomography, PET/CT; Theranostics

Year:  2017        PMID： 29177165      PMCID： PMC5697502          DOI： 10.1159/000480383

Source DB:  PubMed          Journal:  Visc Med        ISSN： 2297-4725


  67 in total

Review 1.  Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.

Authors:  Lisa Bodei; Marta Cremonesi; Chiara Grana; Paola Rocca; Mirco Bartolomei; Marco Chinol; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-19       Impact factor: 9.236

Review 2.  Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms.

Authors:  Richard P Baum; Harshad R Kulkarni; Cecilia Carreras
Journal:  Semin Nucl Med       Date:  2012-05       Impact factor: 4.446

3.  THERANOSTICS-clinical aimshots in surgical warfare against well-differentiated neuroendocrine neoplasms.

Authors:  Dieter Hörsch; Harshad R Kulkarni; Richard P Baum
Journal:  Ann Transl Med       Date:  2014-01

4.  End-stage renal disease after treatment with 90Y-DOTATOC.

Authors:  M Cybulla; S M Weiner; A Otte
Journal:  Eur J Nucl Med       Date:  2001-10

5.  Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

Authors:  Roelf Valkema; Stanislas A Pauwels; Larry K Kvols; Dik J Kwekkeboom; Francois Jamar; Marion de Jong; Raffaella Barone; Stephan Walrand; Peter P M Kooij; Willem H Bakker; Janet Lasher; Eric P Krenning
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

Review 6.  Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy.

Authors:  M Cremonesi; M Ferrari; A Di Dia; F Botta; C De Cicco; L Bodei; G Paganelli
Journal:  Q J Nucl Med Mol Imaging       Date:  2011-04       Impact factor: 2.346

7.  Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.

Authors:  Samer Ezziddin; Mared Attassi; Charlotte J Yong-Hing; Hojjat Ahmadzadehfar; Winfried Willinek; Frank Grünwald; Stefan Guhlke; Hans-Jürgen Biersack; Amir Sabet
Journal:  J Nucl Med       Date:  2014-01-16       Impact factor: 10.057

Review 8.  Pancreatic neuroendocrine neoplasms.

Authors:  D Hörsch; T Bert; J Schrader; M Hommann; D Kaemmerer; A Petrovitch; J Zaknun; R P Baum
Journal:  Minerva Gastroenterol Dietol       Date:  2012-12

9.  Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up.

Authors:  Dieter Hörsch; Samer Ezziddin; Alexander Haug; Klaus Friedrich Gratz; Simone Dunkelmann; Matthias Miederer; Mathias Schreckenberger; Bernd Joachim Krause; Frank M Bengel; Peter Bartenstein; Hans-Jürgen Biersack; Gabriele Pöpperl; R P Baum
Journal:  Eur J Cancer       Date:  2016-03-02       Impact factor: 9.162

Review 10.  Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life.

Authors:  Stefano Severi; Ilaria Grassi; Silvia Nicolini; Maddalena Sansovini; Alberto Bongiovanni; Giovanni Paganelli
Journal:  Onco Targets Ther       Date:  2017-01-27       Impact factor: 4.147
View more
  8 in total

1.  Neuroendocrine Tumors of the Gastrointestinal Tract.

Authors:  Detlef K Bartsch; Hans Scherübl
Journal:  Visc Med       Date:  2017-10-16

Review 2.  The Continuing Evolution of Molecular Functional Imaging in Clinical Oncology: The Road to Precision Medicine and Radiogenomics (Part I).

Authors:  Tanvi Vaidya; Archi Agrawal; Shivani Mahajan; Meenakshi H Thakur; Abhishek Mahajan
Journal:  Mol Diagn Ther       Date:  2019-02       Impact factor: 4.074

3.  Multimodality management, recurrence patterns, and long-term outcome of gastroenteropancreatic neuroendocrine neoplasms: Progress over 17 years.

Authors:  Gunjan S Desai; Prasad Pande; Verushka Chhabra; Rajiv C Shah; Palepu Jagannath
Journal:  Indian J Gastroenterol       Date:  2019-12-04

Review 4.  Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities.

Authors:  Shagufta Shaheen; Farshad Moradi; Gerardo Gamino; Pamela L Kunz
Journal:  Curr Treat Options Oncol       Date:  2020-03-14

Review 5.  [Neuroendocrine tumors : Classification, clinical presentation and imaging].

Authors:  H Scherübl; F Raue; K Frank-Raue
Journal:  Radiologe       Date:  2019-11       Impact factor: 0.635

Review 6.  Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture.

Authors:  Clément Bailly; Caroline Bodet-Milin; Mickaël Bourgeois; Sébastien Gouard; Catherine Ansquer; Matthieu Barbaud; Jean-Charles Sébille; Michel Chérel; Françoise Kraeber-Bodéré; Thomas Carlier
Journal:  Cancers (Basel)       Date:  2019-08-31       Impact factor: 6.639

Review 7.  Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides-Where Are We Now.

Authors:  Mitesh Naik; Adil Al-Nahhas; Sairah R Khan
Journal:  Cancers (Basel)       Date:  2022-02-01       Impact factor: 6.639

8.  Secretin Receptor as a Target in Gastrointestinal Cancer: Expression Analysis and Ligand Development.

Authors:  Anja Klussmeier; Stefan Aurich; Lars Niederstadt; Bertram Wiedenmann; Carsten Grötzinger
Journal:  Biomedicines       Date:  2022-02-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.